Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Our latest work in the life sciences and high-tech fields.
Our work
TMS Co., Ltd. + JiXing Pharmaceuticals + RTW Investments, LP
Strategic Collaboration AgreementsThe firm counseled TMS Co. Ltd. as it entered strategic collaboration agreements with JIXING Pharmaceuticals, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING. TMS regained Japan rights to this compound, received a payment of JIXING equity, and obtained Japan rights to JX09. TMS contemporaneously received a private equity investment from RTW
Press Release
Claris Biotherapeutics, Inc.
Series A-3 Preferred Stock FinancingClaris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors
Press Release
GV (Google Ventures) + ARCH Ventures
Chroma Medicine Series B FinancingRepresentation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing
Press Release
NextPoint Therapeutics, Inc.
Series B Financing - $80 millionNextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management and Dana-Farber Cancer Institute
Website
Paragon Therapeutics, Inc. + Apogee Therapeutics, Inc.
Antibody Discovery and Option AgreementOption for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions
Press Release
6 Dimensions Capital
VC InvestmentsEquity investments in multiple portfolio companies, including Hibercell
Website
Puma Biotechnology, Inc.
Clinical TrialCRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification
See Study
Epalex Corporation
Series A-3 FinancingSeries A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs
Website
Vertex Pharmaceuticals Incorporated
Acquisition of Private CompanyCo-counsel to Vertex on acquisition of ViaCyte, a privately-held biotechnology company that received substantial research funding from the California Institute of Regenerative Medicine
Press Release
Versant Ventures Management, LLC
Antibody Discovery and Collaboration AgreementMulti-year collaboration with AbCellera to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechnology companies
Press Release
Vizgen, Inc.
Series C FinancingVizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors
Press Release
Vernal Biosciences, Inc.
Series A FinancingVernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership
Press Release
Artax Biopharma, Inc. + Advent Life Sciences Fund II LP
Series B Financing (Series B4)Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly
Press Release
Dianthus Therapeutics OpCo, Inc.
Series A FinancingDianthus raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors
Press Release
Summation Bio, Inc.
Series A FinancingSummation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors